Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. Both ...

Trial confirms that oral semaglutide lowers cardiovascular risk in type 2 diabetes, regardless of SGLT2i use. Read more!

Rybelsus® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and/or chronic kidney disease in the SOUL cardiovascular outcomes trial1.Data ...

Earlier in 2025, the U.S. Food and Drug Administration (FDA) approved Ozempic® (semaglutide ... to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease (CKD).

Semaglutide improved maximum walking distance in patients with type 2 diabetes and symptomatic peripheral artery disease.

Recent study shows oral semaglutide reduces cardiovascular risk in type 2 diabetes patients, enhancing diabetes and heart ...

Can you discuss how semaglutide benefited patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease in the SOUL trial and how these results relate to ...

Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building its positions in peripheral artery disease (PAD) and with an oral formulation, based ...

An assessment of the cardiovascular efficacy of oral semaglutide in persons with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both is needed. In this ...

and/or chronic kidney disease (CKD). The study aims to assess the CV efficacy of oral semaglutide regarding the risk of major adverse cardiovascular events (MACE) compared with placebo in persons ...

Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), ...